HeRO News

HeRO News2020-02-25T10:06:53-05:00

MPSC Sponsors Neonatal Ventilation Workshop

MPSC is proud to sponsor the Neonatal Ventilation Workshop presented in association with The Kingdom of Bahrain Ministry of Health and Arabian Gulf University. This workshop will be held February 5th-8th, 2015 at the Arabian Gulf University.

February 16th, 2015|

HeRO exhibiting at the FANNP 2014 conference

MPSC was proud to exhibit the HeRO duet monitor at the Florida Association of Neonatal Nurse Practitioner’s Conference held at the Sheraton Sand Key Resort October 14-18 in Clearwater Beach, Florida. We were delighted to join our local representatives, Bimeco Group, to demonstrate the HeRO System at this educational conference.

October 21st, 2014|

HeRO presentation at SIGNEC

Dr. Karen Fairchild* from the University of Virginia will be presenting “Heart Rate and Cardiorespiratory Analysis for Early Detection of NEC” at the 2nd International Conference on NEC: SIGNEC UK held on Sept 3rd & 4th, 2014 in London.

*Dr. Fairchild is not a paid representative of MPSC nor has any other conflict of interest with HeRO or MPSC, the producer of HeRO.

September 2nd, 2014|

MPSC Releases HeRO Solo for Monitoring NICU Patient Distress

Medical Predictive Science Corporation has broadened its portfolio of life-saving neonatal monitors with HeRO Solo – a turnkey single patient HeRO monitor. HeRO monitors detect early signs of distress in NICU patients, commonly caused by infection and other potentially life-threatening illnesses. In the largest randomized controlled trial ever published among NICU patients, HeRO monitoring reduced mortality by 22%.

Charlottesville, Va. (PRWEB), May 28, 2014 – Medical Predictive Science Corporation announced the immediate release for sale of HeRO Solo, the latest product in the life-saving line of HeRO NICU patient monitoring devices.

“Standing alongside HeRO Symphony, HeRO ES, and HeRO Duet, we now fill out our product portfolio with HeRO Solo,” remarked CEO Will King. He added, “HeRO Solo provides our customers the same life-saving algorithm present in all HeRO products, now in a form factor that simplifies installation and clinical usage to the maximum possible extent.”

HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded.

HeRO monitoring was extensively tested in the largest randomized controlled trial of neonatal patients ever published. In that landmark study, mortality was reduced by 22% percent among those premature infants that received HeRO monitoring, compared with those that did not.

“HeRO Solo will reach a new clinical audience. We expect widespread adoption both outside the US where networking infrastructure in the NICU is less prevalent, as well as inside the US where the move to single bed rooms necessitates bedside monitoring solutions. HeRO Solo will fill both niches,” commented Executive Vice President Geoff Alms.

To learn more about HeRO monitoring, visit www.heroscore.com.

About MPSC
MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a line of products to monitor in-hospital patients.

Contact Information
Media contact
Geoff Alms
434.220.0714 x114
www.heroscore.com
###

May 28th, 2014|

MPSC completes first installation in Wales

MPSC is pleased to welcome Singleton Hospital in Wales to the growing family of HeRO users. We are very proud to work with our partner, SLE Ltd, which represents MPSC in the United Kingdom. SLE helped the customer to successfully receive an innovation grant to deploy the HeRO System in their NICU.

February 4th, 2014|

HeRO video

The HeRO System in use at Timpanogos Regional Medical Center in Orem, Utah.

October 17th, 2013|

HeRO to be presented at MEDNAX meeting

MPSC will be exhibiting HeRO at the Innovations in Neonatal Care: The Surgical Neonate and Fetus meeting held by Pediatrix Medical Group. September 18-20, 2013 at the Grand Hyatt, San Antonio, TX.

September 5th, 2013|

Canadian Patent issued

MPSC announces that Canada Patent No. 2476607 has been issued further extending the intellectual property protection of the HeRO algorithms.

September 5th, 2013|

MPSC receives order for HeRO from Italy

MPSC announces that our Italian distributor, Euromed Italy, has placed an order for HeRO duet. We are proud of this collaboration to introduce HeRO into the Italian Market.

August 29th, 2013|

Introducing HeRO duet

HeRO duet
MPSC is proud to announce the newest member of the HeRO family – HeRO duet.

HeRO duet responds to the requests from our customers for a bedside version of the HeRO System. Using a touchscreen monitor for the interface, HeRO duet is simple to use and install. It was designed to be self-installed at the hospital. Each HeRO duet monitor connects to up to 2 physiological monitors. It supports data collection from the majority of physiological monitors.
HeRO duet logo

August 28th, 2013|

HeRO System Receives Canadian Medical Device License

CHARLOTTESVILLE, Va., December 3, 2012 Medical Predictive Science Corporation (MPSC) announces that it has received a Medical Device License from Health Canada for the Heart Rate Observation System, or HeRO® System. This license allows the device to be marketed and sold in Canada indicated for the prediction of sepsis and improvement in mortality.
 
MPSC CEO Will King commented, “MPSC is very proud to continue building upon the international acceptance of the HeRO System as a safe and effective medical device for infants in the neonatal intensive care units. Adding to the recently received CE marking, HeRO may now be marketed in the European Union, Canada, and the United States.”
 
“MPSC looks to continue upon our recent successes with regulatory submissions in additional countries. HeRO is a quality product supported by the evidence from a large clinical trial which clearly demonstrated safety and effectiveness.” noted Ray Schumin, Director of Regulatory Affairs. “We are very pleased for the receipt of this license from Health Canada,” he added.
 
“MPSC is immediately looking to engage partners or distributors in Canada that want to introduce this life-saving technology into Canadian NICUs. We look to fulfill the requests of potential customers in Canada who have expressed significant interest in the HeRO System and had been eagerly awaiting the availability of HeRO,” remarked Geoff Alms, PhD, Exec. VP of Sales and Marketing.
 
HeRO is a pioneering monitoring system for premature infants that detects early signs of distress, commonly caused by infection and other potentially life-threatening illnesses. HeRO generates an hourly numeric score that quantifies the prevalence of abnormal patterns in each patient’s heart rate and provides a new tool for clinical assessment so that standard diagnostic and therapeutic decisions are better founded.


About MPSC
MPSC is an entrepreneurial medical device company that translates ICU research discoveries to the patient’s bedside. The company develops predictive technology that detects imminent, catastrophic illness. MPSC’s HeRO monitor is the first of a line of products to monitor in-hospital patients.

December 3rd, 2012|
Go to Top